Last reviewed · How we verify
fluorouracil based chemotherapy regimens
Fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis and function.
Fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis and function. Used for Colorectal cancer, Breast cancer, Head and neck cancer.
At a glance
| Generic name | fluorouracil based chemotherapy regimens |
|---|---|
| Sponsor | China Medical University, China |
| Drug class | pyrimidine analog |
| Target | thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a thymidylate synthase inhibitor, fluorouracil blocks the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), a necessary step in DNA synthesis. This leads to DNA damage and cell death, particularly in rapidly dividing cancer cells.
Approved indications
- Colorectal cancer
- Breast cancer
- Head and neck cancer
- Stomach cancer
- Pancreatic cancer
Common side effects
- Mucositis
- Diarrhea
- Nausea
- Vomiting
- Fatigue
Key clinical trials
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (PHASE1, PHASE2)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (NA)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: